Bullish & Foolish
Full CALC fundamentals All 466 on the Survival Watch

CALCCalciMedica, Inc.

Is CalciMedica struggling financially?

Yes, by its own account. CalciMedica told the SEC on 12 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Cries for help

  • Needs to raise money

    To fund our operations in both the near term and long term, we will need to raise additional capital to develop our product candidates and implement our operating plans.

    Form 10-Q, filed 12 May 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$19.6M
Source filing
10-Q 12 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 8months

    If the burn speeds up

    Empty by Mar 2027

  • 13months

    If it eases off

    Empty by Jul 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$18.6M

÷

Cash burned over the last 12 months

$21.2M

What CalciMedica told the SEC

…losses in the future. We have never generated any revenue from product sales and may never be profitable. Our need for additional capital raises substantial doubt about our ability to continue as a going concern. We will need to obtain substantial additional funding to complete the development and any commercialization of our product candidates. If we are unable to raise this capital when…

CalciMedica, Inc., Form 10-Q, filed 12 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 13.1% share-count increase The company issued stock. Each share now owns 11.6% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 44% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt